Cellix Solutions mimic microvascular thrombosis accelerating COVID-19 research
Updated: Aug 28, 2020

For more than 15 years, Cellix has provided researchers with solutions for mimicking physiological conditions of human blood vessels and for quantifying cell adhesion, rolling and migration including platelet adhesion, aggregation, and thrombi formation.
VenaFlux platforms help our customers to study mechanisms in inflammation, cancer, cardiovascular disease, atherosclerosis and thrombosis.
As the SARS-CoV-2 pandemic evolves, there is mounting evidence that the cardiovascular system plays a role in the pathophysiology of COVID-19 disease.